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(adjusted hazard ratio: 0.35; 95% conﬁdence interval: 0.18 to 0.70; p ¼ 0.003).Conclusions Staged CAS-OHS and combined CEA-OHS are associated with a similar risk of death, stroke, or MI in the short term,
with both being better than staged CEA-OHS. However, the outcomes signiﬁcantly favor staged CAS-OHS after the
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to be 6% to 12% (1,2); however, the best approach to
management of concomitant carotid disease in this pop-
ulation remains controversial in the absence of randomized
clinical trials (3–5). Three approaches commonly used are
staged carotid endarterectomy (CEA) followed by open heartSee page 1957surgery (CEA-OHS), combined CEA-OHS (i.e., concomi-
tant CEA and OHS under a single anesthesia), and, more
recently, staged carotid stenting (CAS) followed by OHS
(CAS-OHS) (6). Both staged approaches expose patients to
interstage events such as death, stroke, and myocardial
infarction (MI), especially given the presence of severe
coexisting coronary artery disease.
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1949With combined CEA-OHS, despite eliminating inter-
stage risk, outcomes have been similar to those with staged
CEA-OHS (4,7) and in most cases inferior to those with
staged CAS-OHS, mainly due to higher perioperative stroke
risk (8,9). However, the validity of such comparison is
questionable because of failure to study the impact of inter-
stage events on outcomes after OHS. Furthermore, these
studies have been limited to 30-day or in-hospital endpoints.
Thus, the purpose of this study was to directly compare the 3
approaches addressing these deﬁciencies.Information Registry
HR = hazard ratio
MI = myocardial infarction
NIS = National Inpatient
Sample
OHS = open heart surgery
SSDI = Social Security Death
IndexMethods
Study population. From January 1997 to August 2009, 350
patients underwent a carotid revascularization procedure
within 90 days of planned OHS at Cleveland Clinic: 45
staged CEA-OHS, 195 combined CEA-OHS, and 110
staged CAS-OHS. The study population predominantly
consisted of patients who were found to have severe carotid
artery stenosis on routine duplex ultrasonography as part of
a comprehensive evaluation before OHS. At the time of
OHS, 41 (12%) presented with unstable angina and 25 (7%)
presented with MI. From the carotid standpoint, 66 (19%)
had symptomatic carotid disease (transient ischemic attack or
stroke within 6 months) on the intervened side. Throughout
this paper, we use OHS to refer to either isolated coronary
artery bypass grafting (CABG), CABG combined with
a variety of other cardiac procedures, or non-CABG cardiac
surgery (e.g., isolated valve or aortic repair surgery). Overall,
only 27 (8%) of the OHS were non-CABG procedures. We
mandated the inclusion of only those patients who had both
carotid and OHS procedures at our institution, in part to
eliminate possible bias related to operator expertise or choice
of approach and in part to establish a known intent-to-treat
denominator for staged procedures.
Carotid revascularization and OHS. The approach to
carotid revascularization was approved by a team of cardiolo-
gists and vascular and cardiac surgeons according to medical
practice at that time. Individuals who underwent stagedCAS-
OHS were also examined by a neurologist before CAS and
thereafter on a scheduled basis according to the carotid
stenting protocol. However, for staged and combined CEA-
OHS, neurologists were consulted on an as-needed basis.
CEAwas performed with patients under general anesthesia in
both staged and combined groups. Intraoperative shunting
during CEA and carotid patching were performed at the
discretion of the vascular surgeon. An embolic protection
device was used during CAS in all patients once available
(82%). Cardiac enzymes (creatine kinase–myocardial band or
troponin T) were routinely measured in the ﬁrst 24 h after
CEA or CAS in the staged groups and within 24 h after OHS
in all patients. In the staged CEA-OHS group, OHS was
performed as early as possible; in contrast, staged CAS-OHS
patients were placed on mandatory 3 to 4 weeks of antiplatelet
treatment with aspirin and clopidogrel with consequent delayof OHS unless worsening car-
diac symptoms necessitated early
OHS. Clopidogrel was discon-
tinued 5 days beforeOHS inmost
patients.Cardiopulmonary bypass
(on-pump) and aortic clamping
were used in the majority of
OHS procedures in all 3 groups
(Table 1).
Endpoints. Theprimaryendpoint
was a composite of all-cause
death, stroke, and MI. Secondary
endpoints were components of
the primary endpoint. Median
follow-up for the entire cohort
was 3.7 years from the time of
CEA or CAS. Twenty-ﬁve per-
cent had follow-up for over 7 years
with 10% over 10 years. Stroke
was deﬁned as a new or worsening focal neurological event
that persisted for>24 h.MI within 72 h after OHSwas based
on serum creatine kinase–myocardial band or troponin T
level >5 times the upper limit of normal in the presence of
new pathological Q-wave, new left bundle branch block, or
angiographic evidence ofMI based on the universal deﬁnition
of MI (10). However, beyond this period and during the
interstage interval in stagedCEA andCAS-OHS groups,MI
was diagnosed using serum creatine kinase–myocardial band
or troponin T level >3 times the upper limit of normal in the
presence of symptoms of ischemia or new electrocardio-
graphic ST-segment elevation or depression>1mm in at least
2 contiguous leads or new left bundle branch block.
Data. To obtain the 3 study cohorts, we ﬁrst used the
World Health Organization International Classiﬁcation of
Diseases codes for CEA and CAS supplemented by our
carotid stent registry (11) to identify all carotid revasculari-
zations performed during the study period at our institution.
We then merged these data with our Cardiovascular Infor-
mation Registry (CVIR) (12) to identify OHS within 90
days after carotid revascularization. The CVIR provides data
obtained prospectively from all cardiac surgeries performed at
Cleveland Clinic. Individuals who had CEA or CAS after
OHS were not included. Patient demographic characteris-
tics, extent of coronary disease, type of OHS performed, and
clinical outcomes were obtained from the CVIR. A manual
chart review was subsequently undertaken to obtain carotid
disease symptom status and carotid imaging data and, in
addition, to verify all interstage as well as post-OHS stroke
and MI events. The data from chart review was collected and
managed using REDCap electronic data capture tools hosted
at our institution (13). To accurately ascertain MI and stroke
events that may have occurred outside our institution, all
outpatient follow-up notes were carefully reviewed for such
documentation using our electronic medical record database
until the last follow-up date. We further supplemented
our data by telephone interviews when necessary. All-cause
Table 1 Selected Baseline Characteristics of 350 Patients Stratiﬁed by the 3 Approaches
Characteristics
Staged
CEA-OHS
(n ¼ 45)
Combined
CEA-OHS
(n ¼ 195)
Staged
CAS-OHS
(n ¼ 110) p Value
Demographic and comorbidities
Age, yrs 72  9 (45) 70  8 (195) 71  9 (110) 0.11
Female 11/45 (24) 57/195 (29) 31/110 (28) 0.81
Hypertension 37/45 (82) 171/195 (88) 98/110 (89) 0.50
Pharmacologically treated diabetes 12/43 (28) 79/194 (41) 30/104 (29) 0.07
Diabetes requiring insulin 3/43 (7) 25/193 (13) 10/104 (10) 0.44
Chronic obstructive pulmonary disease 9/45 (20) 37/195 (19) 25/110 (23) 0.74
Smoking 40/44 (91) 144/194 (74) 84/109 (77) 0.06
Chronic kidney disease 5/45 (11) 16/195 (8) 5/110 (5) 0.30
History of peripheral arterial disease 17/42 (40) 68/195 (35) 38/104 (37) 0.78
History of MI 27/42 (64) 96/195 (49) 53/104 (51) 0.21
History of congestive heart failure 13/45 (29) 56/195 (29) 35/110 (32) 0.84
History of atrial ﬁbrillation/ﬂutter 7/37 (19) 6/155 (4) 10/89 (11) 0.01
History of ventricular arrhythmia 8/37 (22) 15/155 (10) 8/89 (9) 0.08
History of OHS 14/45 (31) 15/195 (8) 30/110 (27) <0.001
Left ventricular ejection fraction, % 47  11 (44) 48  12 (185) 48  11 (98) 0.48
CEA and CAS
History of TIA 9/44 (20) 43/194 (22) 27/110 (25) 0.83
History of stroke 6/44 (14) 21/194 (11) 24/110 (22) 0.03
Previous carotid revascularization 5/45 (11) 13/195 (7) 20/110 (18) 0.01
Contralateral carotid 80%–99% stenosis 2/45 (4) 22/195 (11) 6/109 (6) 0.13
Contralateral carotid occlusion 7/45 (16) 24/195 (12) 13/109 (12) 0.81
Symptomatic carotid stenosis on the intervened side 10/45 (22) 32/195 (16) 24/110 (22) 0.42
OHS*
3-vessel coronary artery disease 28/45 (62) 115/187 (61) 52/90 (58) 0.81
Left main disease 14/41 (34) 64/166 (39) 28/83 (34) 0.71
Unstable angina at admission for OHS 6/42 (14) 32/195 (16) 3/104 (3) 0.003
MI at admission for OHS 9/42 (21) 15/195 (8) 1/104 (1) <0.001
Coronary artery bypass graft surgery 35/42 (83) 187/195 (96) 92/104 (88) 0.006
Aortic valve surgery 6/42 (14) 43/195 (22) 35/104 (34) 0.02
Mitral valve surgery 13/42 (31) 19/195 (10) 19/104 (18) 0.001
Any aortic root or ascending aorta or arch surgery 0/42 (0) 11/195 (6) 15/104 (14) 0.003
Any atrial ﬁbrillation procedure 3/42 (7) 1/195 (0.5) 9/104 (9) 0.001
Congenital ASD/PFO suture closure 3/42 (7) 1/195 (0.5) 2/104 (2) 0.01
Aortic cross clamp 40/42 (95) 170/195 (87) 89/104 (86) 0.26
Cardiopulmonary bypass 41/42 (98) 174/195 (89) 90/104 (87) 0.14
Circulatory arrest 0/42 (0) 7/195 (4) 10/104 (10) 0.02
Intra- or post-operative intra-aortic balloon pump 0/42 (0) 3/195 (2) 2/110 (2) 0.68
Values are mean  SD (n representing available patient numbers) or n/N (%) (representing available patient number). *Staged CEA-OHS (n ¼ 42) and staged CAS-OHS
(n ¼ 104) had 3 and 6 interstage deaths, respectively.
ASD ¼ atrial septal defect; CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy; MI ¼ myocardial infarction; OHS ¼ open heart surgery; PFO ¼ patent foramen
ovale; TIA ¼ transient ischemic attack.
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1950mortality was determined by passive follow-up using the
patient’s Social Security number and the Social Security
Death Index (SSDI) (14,15). Use of these data for research
was approved by the Cleveland Clinic Institutional Review
Board, with patient consent waived.
INTERSTAGE DEATH. Because this was an intention-to-treat
analysis, it was important that we identify individuals in
the staged groups who underwent CEA or CAS but died
within 90 days before their planned OHS. For this, we used
the SSDI to ﬁrst identify all deaths within 90 days after
every CEA or CAS performed at our institution during thestudy period. This was followed by a chart review to deter-
mine whether these individuals were scheduled for OHS at
the time of carotid revascularization. Individuals so identi-
ﬁed were included in their respective cohorts. The Carotid
Stent Registry was additionally used to verify deaths among
CAS patients within 90 days.
Statistical analysis. BASELINE CHARACTERISTICS. Baseline
characteristics of the 3 groups were compared using chi-square
test for categorical variables and Kruskal-Wallis nonparametric
test for continuous variables. Most baseline characteristics
did not differ signiﬁcantly among the 3 groups (Table 1).
Speciﬁcally, the prevalence of symptomatic carotid disease,
A B
C D
Figure 1 Unadjusted Comparison of Primary Composite Endpoint and Death in the Study Population According to Approach
(A) Kaplan-Meier curves for the primary composite endpoint are shown for the 3 approaches with CEA or CAS as time zero. The staged CAS-OHS approach was associated with
signiﬁcantly lower composite outcomes overall (log-rank p < 0.001). (B) The 3 groups had similar rates of death (log-rank p ¼ 0.49). (C) Composite outcomes stratiﬁed by OHS
among staged CEA-OHS and staged CAS-OHS patients (time zero reset at OHS). The composite events during the period before OHS (interstage) in the staged CEA-OHS group
explain the signiﬁcant differences seen in A. The interstage events are better illustrated in the expanded view (D). CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy;
OHS ¼ open heart surgery.
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1951contralateral 80% to 99% carotid stenosis, and contralateral
carotid occlusion were similar. However, individuals in the
staged CAS-OHS group had more previous strokes (p¼ 0.03)
and carotid revascularization procedures (p ¼ 0.01). Addi-
tionally, they more frequently underwent complex OHS con-
sisting of CABG combined with aortic valve (p ¼ 0.02) or
aortic repair surgery (p¼ 0.003). To adjust for these differences
in baseline characteristics, we used propensity score method-
ology based on 31 variables (Online Appendix). Because there
are 3 groups, we used polytomous logistic regression analysis to
generate the propensity model. Doing so guarantees that the
calculated set of probabilities representing the 3 propensity
scores for each patient total 100%.
TIME-TO-EVENT ANALYSIS. Time zero for all time-to-event
analyses was the time of CEA or CAS. Freedom from
events was assessed nonparametrically by the Kaplan-Meiermethod (Fig. 1) and parametrically using a multiphase
hazard model that assumed nonproportional hazards over
time (16) (Online Appendix). Two types of time to event
analysis were performed. The ﬁrst was an intention-to-treat
assessment of the 3 strategies from time zero without regard
to when OHS was performed. The second analysis treated
OHS as a time-varying covariable for the staged approaches.
However, a time-varying covariable generally enters such
analysis as a single step change in risk (hazard), and events
after OHS do not behave in this simple fashion. Therefore,
we borrowed from the industrial arena the so-called
modulated renewal method for incorporating a time-
varying covariable. In such an analysis, time zero is reset at
the time of OHS, allowing the early high-risk phase of
hazard to peak and then decline in a manner that ﬁt the data
well. Such an analysis creates virtually 5 mutually exclusive
patient subgroups because the staged CEA-OHS and staged
A B
Figure 2 Competing Risks Analyses for Composite Event During the Interstage Interval for the Staged Approaches
Competing risks graphs for composite event and OHS are shown for staged CEA-OHS (A) and staged CAS-OHS (B). The solid red line, blue line, and black line represent
parametric estimates of the percentage of composite event before OHS, the percentage of OHS before composite event, and the percentage of neither composite event or OHS,
respectively. At any point in time, the sum of percentages of the 3 categories equals 100%. Each red circle, blue square, and black dot represent a composite event before
OHS, OHS before composite event and neither composite event or OHS, respectively based on its time of occurrence during the interstage interval. The dashed lines represent
68% conﬁdence limits. With staged CEA-OHS (A), the composite events peak after CEA before the planned OHS (interstage interval), whereas this does not occur after CAS in
the staged CAS-OHS cohort (B). Abbreviations as in Figure 1.
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1952CAS-OHS approaches each have 2 periods of risk (inter-
stage or before OHS and after OHS): 1) staged CAS, before
OHS; 2) staged CAS, after OHS; 3) staged CEA, before
OHS; 4) staged CEA, after OHS; and 5) combined CEA-
OHS. In presenting analyses of modulated renewal datasets,
we specify the speciﬁc contrasts of interest, obtained by
selecting 1 of these 5 subgroups as the reference group and
incorporating the remaining 4 subgroups in the analysis. We
clearly identify the reference subgroup for speciﬁc contrasts.
The results are presented as adjusted hazard ratio (HR) with
95% conﬁdence interval (CI).
COMPETING RISKS ANALYSIS. For staged patients, competing
risks analyses were conducted to understand how a com-
posite event before OHS competed with OHS within 90
days after CEA or CAS (all patients were expected to have
OHS within 90 days by inclusion criteria) (Fig. 2). In this
analysis, freedom from each event was estimated by a non-
parametric product limit method (17) and the hazard for
each competing event was estimated by the parametric
multiphase hazard method.
RISK-ADJUSTED COMPARISON OF ENDPOINTS. Using propen-
sity score obtained from a parsimonious propensity model
with 31 baseline variables (Online Tables 1 and 2), a base-
line risk-adjusted comparison of 3 groups was performed for
composite endpoint and death. A 5-fold multiple imputa-
tion was used to handle missing data (18). The C-statistic
was indicative of good discrimination (0.84). The propensity
adjusted models were veriﬁed by performing a subgroup
analysis of staged CEA and CAS-OHS cohorts using
propensity matching (Online Fig. 3). In this comparison,
there were 32 matched pairs that represented 71% of thestaged CEA-OHS cohort. The hazard plots for each of
the 3 groups using propensity-adjusted multiphase hazard
function modeling demonstrated overlapping early and late
hazard phases (Fig. 3). Hence, group comparisons were
performed simultaneously for both phases. Nevertheless, the
analyses of early and late events were presented separately,
given their clinical usefulness. Furthermore, to accurately
interpret the results during the early hazard phase in the 2
staged cohorts, separate comparisons were conducted for
interstage composite outcomes and death. All analyses were
performed using SAS statistical software version 9.2 (SAS
Institute, Cary, North Carolina). A detailed description
of the statistical methods used is provided in the Online
Appendix.Results
Interstage events with the 2 staged approaches. The
median staging intervals for CEA-OHS and CAS-OHS
were 14 (interquartile range, 6 to 43) days and 47 (inter-
quartile range, 39 to 61) days, respectively. Of the 9 interstage
deaths, 3 occurred in staged CEA-OHS and 6 in staged
CAS-OHS (p ¼ 0.77) (Table 2). The staged CEA-OHS
group experienced signiﬁcantly higher interstage MI
compared with staged CAS-OHS (24% vs. 3%; p < 0.001),
but interstage strokes were similar (Table 2). Hence, inter-
stage composite events differed signiﬁcantly between staged
CEA-OHS and CAS-OHS cohorts (p < 0.001) (Table 2,
Fig. 1D). In a propensity-adjusted analysis, staged CAS-OHS
had signiﬁcantly lower risk of interstage composite events
(Table 3). Similar results were obtained using propensity-
matched analysis (adjusted HR: 0.33, 95% CI: 0.11 to 0.96;
A B
Figure 3 Adjusted Comparison of Primary Composite Endpoint Using Hazard Plots
Hazard plots using the multiphase model are shown for 3 propensity matched patients, 1 from each cohort to demonstrate early and late hazard phases (A). An expanded view
of early hazard phase (B). The interval to OHS was set to be 2 months for the staged patients. The dashed lines represent 68% conﬁdence limits. (B) The staged approaches are
characterized by 2 peaks of hazard during the early phase consistent with the hazard associated with each procedure. Overall, staged CEA-OHS carries a signiﬁcantly higher risk
of composite outcomes during the early hazard phase driven by interstage events. The hazard curves for staged CAS-OHS and combined CEA-OHS show little separation,
suggesting similar risks during the early phase. At approximately 1 year, the early phase transitions into the late phase, which demonstrates signiﬁcantly lower event rates with
the staged CAS-OHS approach over time. Abbreviations as in Figure 1.
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1953p ¼ 0.04) (Online Table 3). Interstage deaths were similar
between the 2 groups (Online Table 4).
In competing-risks analyses, the composite events peaked
in the perioperative period after CEA (Fig. 2A) before the
planned OHS, driven mainly by interstage MI (Online
Fig. 1); however, this did not occur in the staged CAS-
OHS group (Fig. 2B). Furthermore, in propensity-adjusted
analysis, the interstage interval compared with the rest of
the early hazard phase marked a period of signiﬁcant risk of
composite events with staged CEA-OHS (adjusted HR:
5.47, 95% CI: 1.98 to 15.17; p ¼ 0.001), although this was
not noted with staged CAS-OHS (adjusted HR: 0.95, 95%
CI: 0.37 to 2.48; p ¼ 0.92).
Comparison of all 3 approaches. EARLYHAZARDPHASE. Using
the conventional time interval of 30-days post-OHS (inclusive of
interval deaths), both staged CAS-OHS and combined CEA-
OHS patients had similar unadjusted composite event rates
that were signiﬁcantly lower compared with staged CEA-OHS
patients (p ¼ 0.003). This was for the most part related to more
interstage MIs with staged CEA-OHS (p < 0.001) (Table 2).
Despite the similarity in composite outcomes between staged
CAS-OHS and combined CEA-OHS patients at 30 days post-
OHS, the former had moreMIs (mostly interstage), whereas the
latter experienced more strokes perioperatively (Table 2, Online
Fig. 2). Based on hazard plots using the multiphase model
(Fig. 3A), the period of early risk was substantially longer and
predominated up to approximately 1 year for all groups. During
this time period, the unadjusted composite event rates among
the 3 groups demonstrated similar trends, with the staged CEA-
OHS having the highest risk (Table 2).In propensity-adjusted analysis with the intention-to-treat
approach, the early-phase risk of the composite endpoint
was similar with both staged CAS-OHS and combined
CEA-OHS (adjusted HR: 0.99, 95% CI: 0.61 to 1.62;
p ¼ 0.97) (Table 3). Among the 3 groups, staged CEA-
OHS patients experienced the highest risk. With modu-
lated renewal at OHS, a signiﬁcantly higher interstage risk
was seen with staged CEA-OHS (adjusted HR: 3.74, 95%
CI: 1.78 to 7.89; p < 0.001) but not with staged CAS-OHS
(adjusted HR: 0.76, 95% CI: 0.33 to 1.76; p ¼ 0.52) when
both were compared with combined CEA-OHS (Table 3).
Of note, the period after OHS did not differ signiﬁcantly
among all 3 groups during the early phase (Table 3). Similar
propensity-adjusted analysis for mortality revealed no
differences (Online Table 4).
LATE HAZARD PHASE. Beyond the early hazard phase (>1
year), staged CAS-OHS patients experienced signiﬁcantly
lower risk of composite outcomes compared with combined
CEA-OHS patients (adjusted HR: 0.35, 95% CI: 0.18 to
0.70; p ¼ 0.003) and staged CEA-OHS patients (adjusted
HR: 0.33, 95% CI: 0.15 to 0.77; p ¼ 0.01 (Table 3).
However, staged CEA-OHS and combined CEA-OHS had
a similar risk of composite outcomes (adjusted HR: 1.05, 95%
CI: 0.57 to 1.96; p ¼ 0.87) (Table 3). There were no
differences in mortality among the 3 groups (Online Table 4).
Discussion
Among the 3 common approaches in the management of
concomitant severe carotid and coronary artery disease, our
Table 2
Unadjusted Comparison of Primary and Secondary
Endpoints for the 3 Groups
Events
Staged
CEA-OHS
(n ¼ 45)
Combined
CEA-OHS
(n ¼ 195)
Staged
CAS-OHS
(n ¼ 110) p Value
Interstage interval
Composite* 13 (29) NA 8 (7) <0.001
Death 3 (7) NA 6 (5) 0.77
Stroke 1 (2) NA 1 (1) 0.51
MI 11 (24) NA 3 (3) <0.001
Overall 30-day post-OHSy
Composite* 14 (31) 19 (10) 11 (10) 0.003
Death 3 (7) 9 (5) 7 (6) 0.75
Stroke 1 (2) 13 (7) 2 (2) 0.11
MI 11 (24) 1 (0.5) 3 (3) <0.001
Early hazard phase (1 yr)z
Composite* 18 (40) 33 (17) 18 (16) 0.001
Death 7 (16) 24 (12) 14 (13) 0.84
Stroke 3 (6.7) 17 (8.7) 2 (1.8) 0.06
MI 11 (24) 1 (0.51) 4 (3.6) <0.001
Late hazard phase (>1 yr)z
Composite* 12 (27) 77 (39) 13 (12) <0.001
Death 17 (38) 77 (39) 12 (11) <0.001
Stroke 1 (2.2) 3 (1.5) 0 (0) 0.37
MI 0 (0) 6 (3.1) 3 (2.7) 0.50
Values are n (%). *The composite event includes only the ﬁrst event (death, stroke, or MI) in a given
patient. yOverall event rates during the period from CEA or CAS to 30-day post-OHS inclusive of
interstage events (death, stroke, and MI). zThe early hazard phase outcomes are limited to the
period from CEA or CAS to 1 year based on the approximate duration of its predominance in the
multiphase model. Similarly, the late hazard phase events are shown for the period beyond 1 year
to total duration of study.
MI ¼ myocardial infarction; other abbreviations as in Table 1.
Shishehbor et al. JACC Vol. 62, No. 21, 2013
Carotid Revascularization and Open Heart Surgery November 19/26, 2013:1948–56
1954results demonstrate no signiﬁcant difference in composite
outcomes between staged CAS-OHS and combined CEA-
OHS in the short term. However, beyond 12 months, the
stagedCAS-OHSoption appears to be a better choice. Staged
CEA-OHS has the highest risk during both early and late
phases. These ﬁndings were consistent regardless of multiple
adjustments using propensity score and propensity matching
and adjusting for interstage events among the staged groups.
Competing risks and multiphase analyses with modulated
renewal clearly highlighted the importance of interstage
interval for the staged approaches. During this interval, staged
CEA-OHS, unlike staged CAS-OHS, was associated with
a signiﬁcantly higher risk of interstage MI given the presence
of concomitant severe coronary artery disease.
The staged CAS-OHS and combined CEA-OHS
groups had similar early phase composite outcomes.
However, the staged CAS-OHS group had more interstage
MIs, whereas the combined CEA-OHS group experienced
more periprocedural strokes (Table 2). Furthermore, staged
CAS-OHS was associated with fewer late-phase composite
events, mainly driven by lower mortality (Tables 2 and 3).
Although the exact mechanism for the long-term mortality
advantage of staged CAS-OHS over combined CEA-OHS
is not known, it is possible that the greater number of per-
iprocedural (7% vs. 2%) and up to 1 year (8.7% vs. 1.8%)
strokes seen with combined CEA-OHS could partially
explain this ﬁnding. The differential risk of stroke and MIseen with the 2 approaches is an important ﬁnding that
should be discussed with the patient and considered when
selecting the best approach to treat severe combined carotid
and coronary artery disease.
This study is unique for several reasons. Given the non-
proportional nature of risk over time, a multiphase hazard
model was used rather than the more conventional Cox
model. This enabled stratiﬁcation of risk into 2 distinct, but
overlapping early and late hazard phases. Importantly, the
duration of the early hazard phase (w1 year) indicated that
30-day or in-hospital outcome comparisons may be inade-
quate. Furthermore, with staged approaches, published data
to date have failed to account for the impact of interstage
events on future outcomes. This was addressed in our study
using OHS as a time-varying covariable supplemented by
a modulated renewal process that enables the inclusion of
interstage events as a risk factor for outcomes after OHS. Our
analysis indicates that the interstage events are extremely
important and explain the signiﬁcant outcome differences
among the 3 approaches. Given the greater number of in-
terstage MIs with the staged CEA-OHS strategy, a less
invasive approach using CAS or a combined CEA-OHS
would signiﬁcantly decrease this risk. Despite the avail-
ability of 3 different approaches in this setting, studies thus
far have not reported on simultaneous risk-adjusted 3-group
comparison using a comprehensive time-to-event method-
ology. However, 2-group comparisons reported by Gopaldas
et al. (7), Ziada et al. (8), and Timaran et al. (9) provide useful
insights despite important limitations.
Ziada et al. (8) compared 30-day outcomes among staged
CAS-OHS (n ¼ 56) and combined CEA-OHS (n ¼ 112)
groups. A trend toward fewer strokes or MIs was noted with
CAS-OHS after propensity adjustment (p ¼ 0.06), whereas
no difference was seen for combined death, MI, or stroke
(p ¼ 0.12) (8). Our study extends these ﬁndings by the
addition of a staged CEA-OHS group, a larger sample size,
greater use of embolic protection devices (82% vs. 14%), and
time-to-event analysis accounting for interstage events.
Timaran et al. (9) similarly compared in-hospital outcomes
with staged CAS-OHS (n¼ 887) and combined CEA-OHS
(n ¼ 26,197) using the National Inpatient Sample (NIS)
database. Despite the large sample, the data were limited by
noninclusion of interstage death and MI. In adjusted multi-
variable analysis, the stroke risk increased by 66% with the
combined CEA-OHS strategy. Likewise, the combined
CEA-OHS group experienced more strokes than the staged
CAS-OHS group in our study, with a trend toward signiﬁ-
cance (p¼ 0.06) despite a higher baseline prevalence of stroke
among the latter.
For the 2 CEA-based approaches, Gopaldas et al. (7)
found no signiﬁcant difference for in-hospital death and
stroke in a multivariable analysis using the NIS database.
However, interstage death and MI were not included. The
inclusion of interstage events in our analysis demonstrate
increased risk with staged CEA-OHS compared with
combined CEA-OHS, albeit in the short term.
Table 3
Propensity-Adjusted 2-Staged Group and 3-Group
Comparisons for the Primary Composite Endpoint
HR (95% CI) p Value
Comparison of 2-staged approaches: intention to
treat with modulated renewal at OHS*
(n ¼ 155)
Early hazard phase
Staged CAS before OHS vs. staged
CEA before OHSy
0.19 (0.07–0.53) 0.001
Late hazard phase
Staged CAS-OHS vs. staged CEA-OHS 0.45 (0.17–1.22) 0.12
Comparison of all 3 approaches: intention
to treat (N ¼ 350)
Early hazard phase
Staged CAS-OHS vs. combined CEA-OHS 0.99 (0.61–1.62) 0.97
Staged CEA-OHS vs. combined CEA-OHS 2.03 (1.07–3.88) 0.03
Staged CAS-OHS vs. staged CEA-OHS 0.49 (0.24–1.00) 0.06
Late hazard phase
Staged CAS-OHS vs. combined CEA-OHS 0.54 (0.25–1.18) 0.12
Staged CEA-OHS vs. combined CEA-OHS 0.96 (0.39–2.36) 0.93
Staged CAS-OHS vs. staged CEA-OHS 0.57 (0.20–1.60) 0.28
Comparison of all 3 approaches: intention to
treat with modulated renewal
at OHS* (N ¼ 350)
Early hazard phase
Staged CAS before OHS vs. combined
CEA-OHS
0.76 (0.33–1.76) 0.52
Staged CEA before OHS vs. combined
CEA-OHS
3.74 (1.78–7.89) <0.001
Staged CAS after OHS vs. combined
CEA-OHS
0.63 (0.31–1.30) 0.22
Staged CEA after OHS vs. combined
CEA-OHS
0.65 (0.25–1.67) 0.37
Staged CAS before OHS vs. staged
CEA before OHSy
0.20 (0.08–0.52) <0.001
Staged CAS after OHS vs. staged
CEA after OHS
0.97 (0.15–6.13) 0.98
Late hazard phase
Staged CAS-OHS vs. combined CEA-OHS 0.35 (0.18–0.70) 0.003
Staged CEA-OHS vs. combined CEA-OHS 1.05 (0.57–1.96) 0.87
Staged CAS-OHS vs. staged CEA-OHS 0.33 (0.15–0.77) 0.01
*OHS is a time-varying covariable in the model. The modulated renewal process resets time zero at
OHS for the staged CEA-OHS and staged CAS-OHS groups. yComparison restricted to the interstage
interval.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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1955In summary, the available literature and the ﬁndings of
our study demonstrate a consistent pattern in favor of the
staged CAS-OHS strategy in this population (8,9). Despite
these data, in the United States, only 3% of patients with
concomitant severe carotid and coronary artery disease
undergo staged CAS-OHS (9), suggesting the need to
consider revising our current strategies while we await
a randomized trial.
In the management of concomitant severe carotid and
coronary disease, an important argument in favor of the
combined CEA-OHS approach is urgency to revascularize
the coronary arteries, given that the CAS-OHS strategy
incurs a delay of at least 3 to 4 weeks for dual antiplatelet
therapy before OHS. However, it is important to note that
the majority of combined CEA-OHS procedures areperformed electively: 76% in our study and 77% nationwide
(NIS data) (9). Hence, CAS-OHS would be a feasible
option for most patients. Based on the ﬁndings of this study,
we believe that staged CAS-OHS should be considered
a ﬁrst-line strategy if the 3- to 4-week delay to OHS is
clinically acceptable. Whether multivessel percutaneous
coronary intervention in conjunction with CAS is better or
similar to CABG in this speciﬁc patient population is
a subject that needs to be addressed in the future.
Study limitations. Despite addressing several limitations
with the available literature, this is a single-center study, and
the decision regarding the choice of procedure must always
take into account institutional expertise. Although our
results are based on prospectively collected data, this is
a retrospective study and therefore lacks the advantages of
a double-blind, randomized trial that may account for
unknown confounders. To answer the question of con-
founding related to better operator experience and increased
adoption of CAS over time, we included the interval from
1997 to date of CEA or CAS procedure in the propensity
score analysis. The decision to limit the staging interval to 90
days among the staged cohorts is rather arbitrary. We believe
that most patients with signiﬁcant coronary disease would
have undergone OHS within this time window. Also, the
cause of death could not be reported because such data were
not available through the SSDI. Finally, the lack of a control
group with no carotid intervention is another limitation that
may be difﬁcult to overcome in contemporary practice.
Conclusions
The study found staged CAS-OHS to be comparable to the
combined CEA-OHS approach in the short-term risk of
death, stroke, or MI. However, beyond the ﬁrst year, staged
CAS-OHS is associated with a signiﬁcantly lower composite
risk. Staged CEA-OHS poses a substantial risk of interstage
MI in the OHS population and hence should be avoided if
possible. In choosing between staged CAS-OHS and
combined CEA-OHS, the increased risk of interstage MI
with the former and perioperative stroke with the latter is an
important consideration despite similar risks for the early
composite endpoint.
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APPENDIX
For an expanded methods section and supplemental tables and ﬁgures,
please see the online version of this article.
